Lesinurad (sodium)

Lesinurad sodium is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 μM, respectively.

Product Specifications

CAS Number

[1151516-14-1]

Product Name Alternative

RDEA-594 sodium

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

OAT; URAT1

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Lesinurad-sodium.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O[Na])CSC1=NN=C(Br)N1C2=C3C=CC=CC3=C(C4CC4)C=C2

Molecular Formula

C17H13BrN3NaO2S

Molecular Weight

426.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Shen Z, et al. In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters. Clin Drug Investig. 2016 Jun;36 (6) :443-52|[2]Sattui SE, et al. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8 (4) :145-59.|[3]L.Yeh, et al. RDEA594, a potential uric acid lowering agent througn inhibition of uric acid reuptake , shows better pharmacokinetics rhan its prodrug RDEA806. 2008 ACR/ARHP Annual Scientific Meeting, 24-29 October 2008, USA.